comparemela.com

Tina Cascone News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

United statesBristol myers squibbTina casconeUniversity of texas md anderson cancer centerBoehringer ingelheimMark foundation for cancer researchAmerican joint committee on cancerParker institute for cancer immunotherapySociety for immunotherapy of cancerArrowhead pharmaceuticalsIdeology healthCancer centerAmerican joint committeeNorth americaMark foundationCancer research

Opdivo Before and After Surgery Improves Event-Free Survival in NSCLC

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

United statesTina casconeUniversity of texas md anderson cancer centerDrug administrationCancer center

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone

Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer

Researchers found that the percentage of patients with 18-month event-free survival was 70.2% and 50% in the nivolumab and chemotherapy groups.

United statesTina casconeBristol myers squibbUniversity of texas md anderson cancer centerHealthday newsNew england journalCancer center

Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer

Significantly more patients had 18-month event-free survival in nivolumab versus chemotherapy group.

United statesTina casconeUniversity of texas md anderson cancer centerBristol myers squibbHealthday newsNew england journalCancer center

vimarsana © 2020. All Rights Reserved.